OCX OncoCyte: מכפיל שווי פעילות להכנסות

Biopharmaceutical risks stemming from sanctions are impacting the movement of the EV/Sales valuation multiple on the GURU.Markets chart, where the indicator remains around . Revenue growth is driven by DetermaIO and VitaGraft tests, while operational stability is guaranteed by an established pool of reagent suppliers. This price-to-sales trend helps investors assess the market consensus for OncoCyte Corporation (OCX).
OncoCyte Inc - פילוחים אנליטיים ומדדי מפתח (OCX)

This indicator determines business value through the ratio of market capitalization plus net debt to annual sales volume. By analyzing the firm's valuation via the EV/Sales multiple, an investor assesses the premium paid for future growth rates, which is critical for OncoCyte Corporation (OCX), whose value depends on the successful integration of diagnostic tests into insurance programs and clinical practice.